Spero therapeutics to participate in h.c. wainwright annual bioconnect investor conference

Cambridge, mass., may 16, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that sath shukla, president and chief executive officer of spero therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the h.c. wainwright 2 nd annual bioconnect investor conference at nasdaq, to take place on monday, may 20, 2024, at the nasdaq world headquarters new york, ny. details are as follows:
SPRO Ratings Summary
SPRO Quant Ranking